ArticlePLoS genetics2016
MEF2C and EBF1 Co-regulate B Cell-Specific Transcription.
Article in PLoS genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Identification of a systemic lupus erythematosus disease signature in resting naive B cells.The Journal of clinical investigation · 2026Article
- Lamin B1 safeguards the B cell genome and shapes lymphoma outcome.HemaSphere · 2026Article
- Role of human Myocyte Enhancer Factor 2 (MEF2) proteins in cancer: structural insights, functional diversity, and regulatory mechanisms.Cancer cell international · 2025Review
- Inference of multi-enhancer interactions in T lymphocytes using Hi-Cociety.bioRxiv : the preprint server for biology · 2025Article
- A Comprehensive Bioinformatic Analysis Based on Functional Studies of MEF-2 Family in NSCLC.The Yale journal of biology and medicine · 2025Article
- Integrative miRNA-mRNA profiling uncovers mechanisms of belimumab action in systemic lupus erythematosus.Frontiers in immunology · 2025Article
- An in vitro model of human hematopoiesis identifies a regulatory role for the aryl hydrocarbon receptor.Blood advances · 2023Article
- Article
- Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP-IGH fusion gene.Cancer science · 2023Article
- scANANSE gene regulatory network and motif analysis of single-cell clusters.F1000Research · 2023Article
- EBF1 is continuously required for stabilizing local chromatin accessibility in pro-B cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- A p38α-BLIMP1 signalling pathway is essential for plasma cell differentiation.Nature communications · 2022Article
- The HDAC7-TET2 epigenetic axis is essential during early B lymphocyte development.Nucleic acids research · 2022Article
- Tnpo3 enables EBF1 function in conditions of antagonistic Notch signaling.Genes & development · 2022Article
- IPiScience · 2022Article
- Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer.Bioscience reports · 2021Article
- Type I interferon response-related microglial Mef2c deregulation at the onset of Alzheimer's pathology in 5×FAD mice.Neurobiology of disease · 2021Article
- A Biological Circuit Involving Mef2c, Mef2d, and Hdac9 Controls the Immunosuppressive Functions of CD4+Foxp3+ T-Regulatory Cells.Frontiers in immunology · 2021Article
- A novel MEF2C mutation in lymphoid neoplasm diffuse large B-cell lymphoma promotes tumorigenesis by increasing c-JUN expression.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- A Genetic Screen for Human Genes Suppressing FUS Induced Toxicity in Yeast.G3 (Bethesda, Md.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Hematopoietic stem cells are capable of self-renewal or differentiation along three main lineages: myeloid, erythroid, and lymphoid. One of the earliest lineage decisions for blood progenitor cells is whether to adopt the lymphoid or myeloid fate. Previous work had shown that myocyte enhancer factor 2C (MEF2C) is indispensable for the lymphoid fate decision, yet the specific mechanism of action remained unclear. Here, we have identified early B cell factor-1 (EBF1) as a co-regulator of gene expression with MEF2C. A genome-wide survey of MEF2C and EBF1 binding sites identified a subset of B cell-specific genes that they target. We also determined that the p38 MAPK pathway activates MEF2C to drive B cell differentiation. Mef2c knockout mice showed reduced B lymphoid-specific gene expression as well as increased myeloid gene expression, consistent with MEF2C's role as a lineage fate regulator. This is further supported by interaction between MEF2C and the histone deacetylase, HDAC7, revealing a likely mechanism to repress the myeloid transcription program. This study thus elucidates both activation and repression mechanisms, identifies regulatory partners, and downstream targets by which MEF2C regulates lymphoid-specific differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.